INTRODUCTION {#sec1-1}
============

Recent developments in the pharmaceutical industry have prompted scientists to develop new drug delivery systems such as orally disintegrating tablets (ODTs) for improving patient agreement. ODTs without chewing and need to take water, disintegrate, or dissolve quickly in the mouth cavity.\[[@ref1]\] The United States Food and Drug Administration Center for Drug Evaluation and Research enrolled a regulation which statuses ODTs as "a solid dosage form containing medicinal substances, which disintegrates rapidly, usually within a few seconds, when located on the tongue."\[[@ref2]\] ODTs provide advantages, especially for psychological patients, elderly, and children who have a problem in chewing or swallowing conventional tablets and capsules or pediatric patients with underdeveloped muscular and nervous control that may suffer from ingestion problems.\[[@ref3][@ref4]\] Moreover, ODTs are suitable for patients who may be in trip, with little or no access to water and with continuous nausea.\[[@ref5]\] The result of decrease in disintegration time of tablet cause to fast dissolution and rapid absorption which prepare rapid beginning of clinical effect.\[[@ref6]\] Pregastric absorption of drugs from the mouth may show increased oral bioavailability.\[[@ref7]\] ODTs formulations prepare satisfactory stability, simple manufacturing, precise dosing, small size packing, and relaxed handling by patients.\[[@ref8]\] ODTs consist of wide variety of medicinal active agents covering many therapeutic categories. The disintegration time of ODTs is usually considered to be \<1 min although in most cases, the tablets are disintegrated within 5--30 s. ODTs are specified by low density, hardness, and high porosity.\[[@ref9][@ref10][@ref11][@ref12]\] To prepare ODTs, various technologies such as direct compression, spray drying, freeze drying, and tablet molding were used.\[[@ref13]\]

Montelukast sodium inhibits the cysteinyl leukotriene receptor and is a selective antagonist of leukotriene receptor that used as an alternative to anti-inflammatory medications in the prevention and chronic medication of asthma, exercise-induced bronchospasm, and to relief symptoms of seasonal allergies. It is usually administered orally. Montelukast sodium is a white to off-white colored powder, and it is freely soluble in ethanol, methanol, water, and practically insoluble in acetonitrile. The mean oral bioavailability of montelukast is 64% and more than 99% bound to plasma proteins. Montelukast is extensively metabolized in the liver with cytochromes P450 3A4 and 2C9. Montelukast sodium is available in various dosage forms such as 10 mg film-coated tablet, 4 and 5 mg chewable tablets, and 4 mg oral granules sachet.\[[@ref14][@ref15][@ref16]\] A solution of montelukast when exposed to sunlit showed instability and lead to the creation of its cis-isomer as the main photolized product.\[[@ref17]\]

The aim of this study was to design, formulate, and evaluate the physicochemical properties of 5 mg montelukast ODTs to decrease disintegration time of tablet in the oral cavity and hence to improve patient compliance for prevention of asthma and seasonal allergies.

METHODS {#sec1-2}
=======

Materials {#sec2-1}
---------

The pharmaceuticals including montelukast sodium were provided from Cobeldarou Pharmaceutical Company (Tehran, Iran). The super disintegrants such as crospovidone (CP), sodium starch glycolate (SSG), and croscarmellose sodium (CCS) and flavoring agents were provided from Farabi Pharmaceutical Company (Isfahan, Iran). Citric acid, sodium bicarbonate, tartaric acid, mannitol, microcrystalline cellulose, aspartame, sodium lauryl sulfate (SLS), magnesium stearate, and polyethylene glycol 6000 were purchased from Merck Company (Germany).

Spectrophotometric analysis {#sec2-2}
---------------------------

Different aliquots (0.5--8 ml) of a standard solution containing 40 μg/ml montelukast sodium were moved into sequences of 10 ml volumetric containers, and they were diluted with 0.5% of SLS in water. Determination of montelukast sodium was done by spectrophotometry (Shimadzu UV-1240 model) at 346 nm.\[[@ref18]\] This experiment was repeated three times a day in 3 consecutive days.

Preformulation {#sec2-3}
--------------

At first, some initial formulations were prepared based on a range of values of super disintegrating agents such as CCS, SSG, and CP and some initial formulations were made up with different amounts of effervescent components such as citric acid, tartaric acid, and sodium bicarbonate \[Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}\]. Lower amounts of super disintegrating agents which had disintegration time under 1 min were screened out and used for the final formulations of tablets for combination whether together or with effervescent bases which had lowest disintegration time.

###### 

Initial formulations of montelukast orally disintegrating tablets with various percent of super disintegrants
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###### 

Initial formulations of montelukast orally disintegrating tablets with various ratios of effervescent bases
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Evaluation of powder mixture {#sec2-4}
----------------------------

The angle of repose, compressibility index, and Hausner\'s ratio characterized the flowability properties of blended powders before compression.

Angle of repose (θ) {#sec2-5}
-------------------

Angle of rest is an index of the frictional forces in a powder blend. It is determined as the most possible angle that powder mass created by the horizontal plane. The pile of blend was permitted to flow to a stand at a fixed height through a cone fixed. By measuring the height (H) and diameter (D) of the formed powder mass and putting the values into the formula, the angle of repose (θ) was calculated:\[[@ref19]\]

Tan θ = (2H/D)      Eq. (1)

Compressibility index {#sec2-6}
---------------------

The compressibility index is evaluated by measured values for bulk density (ρ~b~) and tapped density (ρ~t~) of mixed powder. The compressibility index percentage was computed as:\[[@ref19][@ref20]\]
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In these equations, ρ tapped and ρ bulk are:
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*m*: Initial weight of powder,

V bulk: Initial volume of powder before hitting,

V tapped: Second volume of powder after hitting.\[[@ref19]\]

Hausner\'s ratio {#sec2-7}
----------------

Hausner\'s ratio indicates the flow property of mixed powders. This ratio can be measured by the next equation:\[[@ref19][@ref21]\]
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Tablets preparation {#sec2-8}
-------------------

By direct compression technique, montelukast ODTs were prepared by effervescent and super disintegrants bases. According to Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, materials of each formulation were weighed and then montelukast sodium was added to each formulation. Fruit flavoring agents were added to formulations for evaluating taste. Finally, after preparation of appropriate mixture, lubricant was added. Then, the ingredients were mixed in the geometrical method; they were compressed into tablets using 8 mm round flat punches (Kilian and Co., Germany).

###### 

Ingredients for final formulations of montelukast orally disintegrating tablets with super disintegrants and their mixtures
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###### 

Ingredients for final formulations of montelukast orally disintegrating tablets with mixture of super disintegrants and effervescent bases
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Physicochemical evaluation of the prepared tablets {#sec2-9}
--------------------------------------------------

### Weight variation {#sec3-1}

Twenty tablets were randomly selected and weighed individually, and the mean weight was calculated. In this test, not more than two tablets should have a deviation greater than pharmacopeia limits (±7.5% of the weight tablet).\[[@ref22][@ref23]\]

### Friability test

Ten tablets were weighed and placed in the friabilator machine (Erweka, TAP, Germany). This instrument was installed on Erweka motor and turned on the speed of 25 rpm for 4 min. The segregated particles of the tablets were carefully removed, and tablets were reweighed. Friability percentage was obtained from the following equation.\[[@ref23]\]
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### Thickness test {#sec3-2}

In this test, thickness of ten tablets was randomly measured by a vernier caliper (For-Bro Engineers, India). The variation range of thickness should not be out of 5% of normal standard.\[[@ref23]\]

### Hardness test {#sec3-3}

Hardness of ten tablets was checked individually using hardness equipment in N scale (Erweka, 24-TB, Germany) In ODTs, this value was generally less than formal tablets.\[[@ref23]\]

### Assay {#sec3-4}

Twenty tablets were weighed and comminuted. The powder equal to one tablet was considered exactly and in 25 ml of SLS 0.5% in water dissolved. The consequent solution was filtered by filtration paper and then the following dilutions were carried out. The diluted solution absorbance was calculated from the consequent equation of the montelukast in SLS 0.5% in water at 346 nm.

### Content uniformity {#sec3-5}

Ten tablets selected by chance, then the content of each pill was measured distinctly.\[[@ref18]\]

### In vitro disintegration time {#sec3-6}

The test was carried out on six tablets using the fixed basket containing six cylindrical glass tubes, the bottom of each tube is connected to a stainless steel basket with certain mesh. The disintegration media was purified water at 37°C ± 2°C and the time that disintegration of the tablet was completed in the apparatus was recorded in seconds.\[[@ref24]\]

### Wetting time {#sec3-7}

A piece of twice-folded tissue paper was put into 6 ml of water in a Petri dish. A pill was located on the tissue paper, when wetting was completed the time recorded.\[[@ref25]\]

### Dissolution test {#sec3-8}

Montelukast sodium ODTs dissolution test was carried out with United State Pharmacopeia (USP) dissolution apparatus Type II (paddle) at 50 rpm with dissolution medium of SLS 0.5% in purified water at 37°C ± 0.5°C.\[[@ref26]\] At times of 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 min, 5 ml sample was removed and substituted by new media. The concentration of samples was measured by ultraviolet (UV) spectrophotometry (Shimadzu UV-1240 model) at 346 nm.

Evaluation of flavor of the prepared tablets {#sec2-10}
--------------------------------------------

To evaluate the taste, panel tests performed by the Latin square method. At first, formulations were prepared with various flavoring agents such as cherry, tutti-frutti, orange, and without flavor but the same amounts of sweeteners and the same content of active drug and excipients. Twenty healthy volunteers were selected and divided into four groups: The first group was given cherry (A), tutti-frutti (B), orange (C), and without flavoring agents (D). The second group: B, C, D, and A; third: C, D, A, and B; and the fourth group was the D, A, B, and C. Then, the volunteers were asked to score each of the formulation from 1 to 5 (1: bad, 2: poor, 3: average, 4: good, and 5: very good taste).\[[@ref27]\]

Moisture uptake study {#sec2-11}
---------------------

Moisture uptake studies for ODTs provide some good information of formulation stability; therefore, moisture uptake study is an important study in the case of ODTs.

Moisture uptake studies were carried out by weight method. For complete drying of the tablets, ten tablets were kept in the desiccators over calcium chloride at temperature 37°C for 24 h. At room temperature, the tablets were weighed and exposed to 75% relative humidity (RH) for 2 weeks. By keeping saturated sodium chloride solution at the bottom of the desiccators for 3 days the required humidity was achieved. Pills were reweighed, and an increase in weight was reported in percentage.\[[@ref28][@ref29]\]

RESULTS {#sec1-3}
=======

The standard curves of montelukast sodium in 0.5% SLS in purified water led to the curve equation, *y* = 0.0649*x* + 0.0252 and *R*^2^ = 0.997.

The S~2~, S~5~, S~7~ and S~2~ S~5~, S~2~ S~7~, S~5~ S~7~ formulations were designed with super disintegrating agents \[[Table 3](#T3){ref-type="table"}\]. The E~8~S~2~, E~9~S~2~, E~8~S~5~, E~9~S~5~, E~8~S~7~, and E~9~S~7~ formulations were prepared with a combination of super disintegrating agents and effervescent bases \[[Table 4](#T4){ref-type="table"}\]. Results from the evaluation of the mixed powders including bulk density, tapped density, angle of repose, compressibility index, and Hausner\'s ratio are given in [Table 5](#T5){ref-type="table"}. The results obtained from tablets evaluation including weight variation, friability, thickness, hardness, disintegration time, wetting time, content uniformity, and assay are presented in [Table 6](#T6){ref-type="table"}. An average weight of twenty tablets of all formulations with super disintegrating and combination super disintegrating with effervescent base was found in the range of 147--150 mg and 198.5--200.5 mg, respectively. The range of friability, thickness, and hardness of all the formulations was described in 0.27%--0.43%, 3.00--3.81 mm, and 33.7--37.1 N, respectively. Wetting time was found in the range of 31--50 s, which facilitate the faster dispersion in the mouth. Drug content of all formulations was found in the range of 96.28%--99.90%.

###### 

Physical characteristics evaluation of powder mixture (*n*=3)
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###### 

Physicochemical evaluation of montelukast orally disintegrating tablets (*n*=3)

![](IJPVM-7-120-g010)

The *in vitro* disintegration time of the tablets was found in the range of 30--50 s in formulations with super disintegrating agents and 20--36 s in formulations with a combination of super disintegrating and effervescent bases. *In vitro* dissolution studies of formulations at different time intervals are shown in [Figure 1](#F1){ref-type="fig"}.

![*In vitro* release of montelukast orally disintegrating tablets in 0.5% of SLS in purified water at 37°C (*n* = 3)](IJPVM-7-120-g011){#F1}

The results of taste evaluation are shown in [Figure 2](#F2){ref-type="fig"}. According to the average assigned scores, the tutti-frutti flavor receives the highest score. Moisture uptake studies for formulations were performed at 75% RH, and the results were in the range of 0.2%--0.5%.

![The results of taste evaluation of montelukast orally disintegrating tablets in panel tests by Latin-square method (*n* = 20)](IJPVM-7-120-g012){#F2}

DISCUSSION {#sec1-4}
==========

Montelukast sodium is a selective and orally active leukotriene receptor antagonist that used as an alternative to anti-inflammatory medications in the prevention and chronic treatment of asthma, alleviation of symptoms of seasonal allergies, and exercise-induced bronchospasm. This drug is available in the form of oral tablets and granules. Montelukast 5 mg chewable tablet is mostly used for prevention and treatment of asthma or allergic rhinitis, especially in children who have difficulty in swallowing or chewing conventional tablets.

The aim of this study was to design, formulate, and evaluate the physicochemical properties of montelukast ODTs to decrease disintegration time of tablet in the buccal and hence, to improve patient compliance.

Montelukast sodium standard curve in 0.5% SLS in purified water was plotted by UV spectrophotometry at λ~max~ of 346 nm. The results of this curve helped us for determination of the assay and content uniformity test.

The S~1~--S~9~ formulations were designed with a different amount of SSG (2%--8%), CCS (0.5%--5%), and CP (2%--5%). The final formulations were selected with the best disintegration time at a lower amount.\[[@ref30]\] S~2~S~5~, S~2~S~7~, and S~5~S~7~ formulations were prepared with a combination of super disintegrating agents. The E~1~--E~9~ formulations were made up different effervescent components such as citric acid, tartaric acid, and sodium bicarbonate. According to the neutralization of alkali and acid and the ratios between them, concentration of each effervescent bases was determined,\[[@ref31]\] but disintegration time of the tablets was found to be more than 60 s, so for decreasing disintegration time, E~8~ and E~9~ formulations that had the lowest disintegration time were combined with S~2~, S~5~, and S~7~ formulations. E~8~S~2~, E~9~S~2~, E~8~S~5~, E~9~S~5~, E~8~S~7~, and E~9~S~7~ formulations were prepared with a combination of super disintegrant agents and effervescent bases.

The angle of repose is better obvious for flow property of all mixed powders. In this study, the angle of repose was in the range of 32.93--34.65. According to the USP specifications the flow properties of the powder blend, all formulations had medium to good flow. In the other study, on piroxicam ODTs angle of repose was in the range of 28.6--34.7\[[@ref32]\] that confirms our results.

The hardness of ODTs is less than conventional tablets that in this study were observed in the range of 33.7--37.1 N, in other studies on ODTs of ondansetron, metoclopramide, and rizatriptan hardness of tablet were reported between 20 and 40 N\[[@ref33][@ref34][@ref35]\] that showed the results were agreement with this study.

Friability values were \<1% in all formulations (0.27%--0.43%). In another study, friability was in the range of 0.33%--0.66 and confirms our results.\[[@ref32]\] The results of hardness and friability indicated that the tablets had suitable mechanical strength at the time of handling and transportation.

In the tablets, which their weight is between 130 and 324 mg, just two tablets can be exceed from ± 7.5% of the weight average (for tablets with 200 mg weight ± 15 mg and for tablets with 150 mg weight ± 11.25 mg)\[[@ref23]\] that all tablets were in the range.

The content uniformity test was for the determination of fixed dose of medicine in individual tablets. Content uniformity of tablets was in acceptable 85%--115% limitation (96.28%--99.90%), which showed powders were uniformly mixed before tableting. All formulations had passed assay test successfully.

Disintegration time is the most important test in the preparation of ODTs. The shorter the disintegration time, the better it would be accepted by patients. Disintegration time of the tablets prepared with super disintegrating agents, effervescent bases, and combination of two was found to be in the range of 30--50, more than 60 and 20--36 s, respectively. The S~2~S~7~ and S~5~S~7~ between formulations prepared by super disintegrant agents and E~9~S~7~ between formulations combination of super disintegrant agents with effervescent bases were found to have shorter disintegration time. Swelling and effervescence are two mechanisms that was disintegrated tablets. In other studies, the disintegration time with super disintegrant agents has been reported between 9 and 72 s.\[[@ref33][@ref34][@ref35]\]

The wetting time was in the range of 31--50 s. This time in most formulations was longer than disintegration time since the tablet remained in plate level and was not soaked in water. In other studies, the wetting time has been reported between 9 and 75 s.\[[@ref32][@ref33][@ref34]\] The difference in results can be related to kind of super disintegrant and ingredients and contact surface too. In similar study, the disintegration time was found to be in the range of 8--40 s, while the wetting time was found to be in the range of 13--40 s, also was observed that when CCS was used as disintegrant, the tablets disintegrated rapidly compared to CP and SSG,\[[@ref36]\] but in this study, the tablets disintegrated rapidly with CP.

*In vitro* dissolution studies of formulations at different time intervals showed that drug release profiles of all formulations are the same and most formulations released 50% of the drug within 30 s. In other study, on ODTs of montelukast sodium with similar details of the dissolution test most formulations released 50% of the drug within 60 s.\[[@ref18]\] This may be due to the difference in the method of preparation of tablets. According to the average assigned scores, the tutti-frutti flavor was chosen by volunteers. Moisture uptake studies for formulations were performed at 75% RH, and there was a slight moisture uptake observed in tablets. Hygroscopicity of most formulations leads to special packing requirements for ODTs.

CONCLUSIONS {#sec1-5}
===========

The present work was aimed to formulate the ODT of montelukast sodium using super disintegrants, effervescent bases, and mixture of two. The results from *in vitro* disintegration time showed that the formulations prepared with super disintegrants and super disintegrants combined with effervescent bases were more beneficial than the formulations with effervescent bases alone. Formulation E~9~S~7~ showed minimum disintegration time compared to other formulations. S~7~ containing CP showed minimum disintegration time between formulations with super disintegrants.
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